Compare NVAX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVAX | DMRA |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 1996 | 2020 |
| Metric | NVAX | DMRA |
|---|---|---|
| Price | $9.32 | $24.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $11.33 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 4.9M | 283.9K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 309.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,123,479,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 64.69 | N/A |
| 52 Week Low | $6.20 | $16.50 |
| 52 Week High | $11.85 | $28.76 |
| Indicator | NVAX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 46.42 |
| Support Level | $9.14 | $22.71 |
| Resistance Level | $10.66 | $28.00 |
| Average True Range (ATR) | 0.68 | 1.63 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 50.82 | 43.57 |
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.